Sunny Pandita, MD
Pulmonary Disease · Murray, UTNPI 1023095809
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Mylan Specialty L.p. at 33.0% of the total. Reporting peaked in 2023 at $6,227 and has fallen 70.1% since, to $1,861 in 2025. Among pulmonary disease clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 678 payments — averaging $36.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$8K
- AstraZeneca$6K
- Inspire Medical Systems, Inc.$2K
- GSK$1K
- Boehringer Ingelheim$925
- Harmony Biosciences LLC$527
- plus $5K from 41 others
What the payments were for
- Consulting fees$8704%
- Speaking & faculty fees$9,73940%
- Travel & lodging$1,6767%
- Food & beverage$12,02049%
- Education$2331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$7,071
- BREZTRI$4,175
- Inspire$1,369
- Inspire Upper Airway Stimulation System$148
- Wakix$120
How this compares
$24,539 in reported general payments places this provider in the 90th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $153,018 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 191 | $143,484 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 103 | $64,538 |
| Spiriva RespimatTiotropium Bromide | 72 | $57,138 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 325 | $52,887 |
| SymbicortBudesonide/Formoterol Fumarate | 91 | $36,635 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $29,372 |
| EliquisApixaban | 18 | $23,102 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $16,344 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $14,713 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $11,217 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 41 | $9,071 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $8,812 |
| Qvar RedihalerBeclomethasone Dipropionate | 25 | $8,352 |
| Atrovent HfaIpratropium Bromide | 14 | $6,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,157 | $214,463312 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $6,326 | $180,120282 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $925 | $121,676175 claims |
| PfizerEliquis | $156 | $23,10218 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $145 | $8,35225 claims |
| Johnson & JohnsonXarelto | $17 | $5,63011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Murray
- Timothy LeclairMurray$74K
- Meghan CirulisMurray$18K
- David GuidryMurray$11K
- David DienhartMurray$11K
- Lynette BrownMurray$10K
- Gregory GrandioMurray$6K
- Katie JeansMurray$3K
- Mark DodsonMurray$2K
- Samuel BrownMurray$1K
- Jeffrey GrahamMurray$408
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.